NASDAQ:CMRA Comera Life Sciences (CMRA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends Get Comera Life Sciences alerts: Email Address About Comera Life Sciences Stock (NASDAQ:CMRA) 30 days 90 days 365 days Advanced Chart Ad Paradigm PressKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election Meltdown” coming this November.Click here now to see Jim’s shocking predictions for November. Get Comera Life Sciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.02▼$0.0352-Week Range N/AVolumeN/AAverage VolumeN/AMarket Capitalization$682,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewComera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.Read More… Kamala Harris and The Woke Progressive Nightmare (Ad)New research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election Meltdown” coming this November.Click here now to see Jim’s shocking predictions for November. Receive CMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Comera Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CMRA Stock News HeadlinesCarisma Therapeutics to Join Citizens JMP Life Sciences ConferenceMay 13, 2024 | msn.comComera Life Sciences Announces Sweeping Workforce TerminationJanuary 31, 2024 | msn.comWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 18, 2024 | Porter & Company (Ad)Comera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionJanuary 4, 2024 | finance.yahoo.comComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionJanuary 4, 2024 | finance.yahoo.comComera Life Sciences to explore strategic alternativesDecember 6, 2023 | msn.comComera Life Sciences Announces Process Exploring Strategic AlternativesDecember 6, 2023 | finance.yahoo.comComera Life Sciences Stock (NASDAQ:CMRA), Analyst Ratings, Price Targets, PredictionsNovember 26, 2023 | benzinga.comSee More Headlines CMRA Stock Analysis - Frequently Asked Questions How do I buy shares of Comera Life Sciences? Shares of CMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today9/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMRA CUSIPN/A CIK1907685 Webcomeralifesciences.com Phone617-871-2101FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.00 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.37) per share Price / BookN/AMiscellaneous Outstanding Shares30,738,000Free Float28,002,000Market Cap$682,000.00 OptionableNot Optionable Beta0.13 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CMRA) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredCrypto ‘Banana Zone’ Incoming…What if I told you that bananas could make you a millionaire? No, this isn't a joke – I'm talking about the...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Comera Life Sciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Comera Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
